Medivir outlicenses the antiviral compound MIV-160 to Guangdong Lantai Viewland Pharmaceutical Co. Ltd

14-Feb-2007

Medivir AB and Guangdong Lantai Viewland Pharmaceutical, China, announced the signing of a licensing agreement on MIV-160 (MV026048), a non-nucleoside HIV reverse transcriptase inhibitor (NNRTI) in late pre-clinical development.

Under the terms of the agreement Guangdong Lantai Viewland Pharmaceutical will make a payment to Medivir by transferring equity. In addition Guangdong Lantai Viewland Pharmaceutical will pay royalties on sales for both oral and topical use of MIV-160. Guangdong Lantai Viewland Pharmaceutical will have responsibility for the development of MIV-160 and commercialization in China (including Hong Kong, Taiwan and Macao). Medivir retains the rights to MIV-160 for all others territories.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance